Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 6/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | NRAS | P01111 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17300794 | 0.85 | NPSR1 (0.37) | HRH4FLT3HRH3IRAK4NRAS | |
| SCHEMBL17300778 | 0.85 | HRH3 (0.34) | HRH4FLT3HRH3HRH2 | |
| SCHEMBL17300780 | 0.83 | HRH4 (0.42) | HRH4HSD17B10PDGFRBPDGFRA | |
| SCHEMBL17304012 | 0.81 | FLT3 (0.39) | FLT3HRH3EHMT2IRAK4NRAS | |
| SCHEMBL17300826 | 0.81 | HRH3 (0.39) | HRH4FLT3HRH3IRAK4HRH2 | |
| SCHEMBL17300798 | 0.77 | HRH3 (0.36) | HRH4FLT3HRH3HRH2 | |
| SCHEMBL17300822 | 0.77 | HRH4 (0.42) | HRH4FLT3HRH3HRH2 | |
| SCHEMBL17300777 | 0.77 | MALT1 (0.39) | HRH4FLT3HRH3HRH2SSTR4 | |
| SCHEMBL15829874 | 0.77 | FLT3 (0.37) | FLT3HRH3EHMT2IRAK4NRAS | |
| SCHEMBL17306708 | 0.74 | DDB1 (0.39) | FLT3EHMT2NRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HRH4 1096/4885FLT3 791/4885HRH3 1072/4885 |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | HRH4 530/4885FLT3 1014/4885HRH3 629/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HRH4 1689/4885FLT3 560/4885HRH3 1549/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HRH4 530/4885FLT3 1014/4885HRH3 629/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HRH4 945/4885FLT3 307/4885HRH3 1208/4885 |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HRH4 1096/4885FLT3 791/4885HRH3 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.